Shots:

• The P-Ib study involves assessing of Ipatasertib + Tecentriq + CT (paclitaxel/nab-paclitaxel) in 26 patients with locally advanced or metastatic TNBC
• P-Ib study results: ORR 73%; median duration of follow-up 6.1 mos.; Grade ≥3 AEs 54%; all-grade AEs 88%- Presented at AACR 2019
• Ipatasertib is an oral selective AKT inhibitor targeting three isoforms of AKT further blocking the PI3K/AKT signaling pathway and was developed in collaboration with Genentech & Array BioPharma

Ref: Roche | Image: Roche